TScan Therapeutics (NASDAQ:TCRX) Rating Reiterated by HC Wainwright

TScan Therapeutics (NASDAQ:TCRX – Get Rating)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $15.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 411.95% from the stock’s previous close.

TScan Therapeutics Price Performance

Shares of NASDAQ:TCRX opened at $2.93 on Thursday. The firm’s 50 day moving average is $2.32 and its two-hundred day moving average is $2.52. TScan Therapeutics has a 52 week low of $1.45 and a 52 week high of $4.56. The firm has a market capitalization of $70.55 million, a P/E ratio of -1.07 and a beta of 0.44. The company has a current ratio of 8.51, a quick ratio of 8.51 and a debt-to-equity ratio of 0.25.

Institutional Investors Weigh In On TScan Therapeutics

Several large investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in shares of TScan Therapeutics in the fourth quarter valued at approximately $31,000. Alphabet Inc. acquired a new position in shares of TScan Therapeutics during the third quarter valued at approximately $3,285,000. Vanguard Group Inc. increased its stake in shares of TScan Therapeutics by 13.9% during the third quarter. Vanguard Group Inc. now owns 257,416 shares of the company’s stock valued at $785,000 after acquiring an additional 31,352 shares during the period. Prudential Financial Inc. acquired a new position in shares of TScan Therapeutics during the third quarter valued at approximately $34,000. Finally, Privium Fund Management UK Ltd acquired a new position in shares of TScan Therapeutics during the third quarter valued at approximately $48,000. Institutional investors and hedge funds own 48.21% of the company’s stock.

TScan Therapeutics Company Profile

(Get Rating)

TScan Therapeutics, Inc, a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.